医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges

摘要Chemotherapy-induced neutropenia (CIN) is a potentially fatal and common complication in myelosuppressive chemotherapy. The timing and grade of CIN may play prognostic and predictive roles in cancer therapy. CIN is associated with older age, poor functional and nutritional status, the presence of significant comorbidities, the type of cancer, previous chemotherapy cycles, the stage of the disease, specific chemotherapy regimens, and combined therapies. There are many key points and new challenges in the management of CIN in adults including: (1) Genetic risk factors to evaluate the patient's risk for CIN remain unclear. However, these risk factors urgently need to be identified. (2) Febrile neutropenia (FN) remains one of the most common reasons for oncological emergency. No consensus nomogram for FN risk assessment has been established. (3) Different assessment tools [e.g., Multinational Association for Supportive Care in Cancer (MASCC), the Clinical Index of Stable Febrile Neutropenia (CISNE) score model, and other tools] have been suggested to help stratify the risk of complications in patients with FN. However, current tools have limitations. The CISNE score model is useful to support decision-making, especially for patients with stable FN. (4) There are still some challenges, including the benefits of granulocyte colony stimulating factor treatment and the optimal antibiotic regimen in emergency management of FN. In view of the current reports, our group discusses the key points, new challenges, and management of CIN.

更多
广告
作者 Yi Ba [1] Yuankai Shi [2] Wenqi Jiang [3] Jifeng Feng [4] Ying Cheng [5] Li Xiao [6] Qingyuan Zhang [7] Wensheng Qiu [8] Binghe Xu [2] Ruihua Xu [3] Bo Shen [4] Zhiguo Luo [9] Xiaodong Xie [10] Jianhua Chang [9] Mengzhao Wang [11] Yufu Li [12] Yuerong Shuang [13] Zuoxing Niu [14] Bo Liu [14] Jun Zhang [15] Li Zhang [3] Herui Yao [16] Conghua Xie [17] Huiqiang Huang [2] Wangjun Liao [18] Gongyan Chen [7] Xiaotian Zhang [19] Hanxiang An [20] Yanhong Deng [21] Ping Gong [22] Jianping Xiong [23] Qinghua Yao [24] Xin An [3] Cheng Chen [4] Yanxia Shi [3] Jialei Wang [9] Xiaohua Wang [4] Zhiqiang Wang [3] Puyuan Xing [2] Sheng Yang [2] Chenfei Zhou [15] 学术成果认领
作者单位 Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China [1] Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China [2] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China [3] Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China [4] Department of Oncology, Jilin Province Cancer Hospital, Changchun 130012, China [5] Department of Oncology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen 361004, China [6] Department of Oncology, Cancer Hospital Harbin Medical University, Harbin 150081, China [7] Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao 266003, China [8] Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China [9] Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China [10] Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Beijing 100730, China [11] Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China [12] Lymphoma and Myeloma Department, Jiangxi Cancer Hospital, Nanchang 330029, China [13] Department of Medical Oncology, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Jinan 250117, China [14] Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China [15] Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China [16] Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430070, China [17] Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China [18] Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China [19] Department of Medical Oncology, Xiang'an Hospital of Xiamen University, Xiamen 361101, China [20] Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China [21] Department of Oncology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832000, China [22] Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China [23] Department of Integrated Chinese and Western Medicine, Cancer Hospital of University of Chinese Academy of Science, Zhejiang Cancer Hospital, Hangzhou 310022, China [24]
栏目名称
DOI 10.20892/j.issn.2095-3941.2020.0069
发布时间 2020-12-15(万方平台首次上网日期,不代表论文的发表时间)
提交
  • 浏览31
  • 下载5
癌症生物学与医学(英文版)

癌症生物学与医学(英文版)

2020年17卷4期

896-909页

SCIMEDLINEISTICCSCDCABP

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷